The global injectable drug delivery market size is expected to reach USD 1,317.38 Billion in 2030 and register a revenue CAGR of 12.8% during the forecast period. Injectable drug delivery market revenue growth is primarily driven by factors such as rising demand for pre-filled syringes and pen-injectors due to ease of administration and rapid technological advancement in drug delivery systems. In addition, increasing adoption of injectable drug delivery systems due to rising prevalence of chronic diseases and emerging research initiatives for delivery of drugs through nanofibers are other factors projected to drive revenue growth of the injectable drug delivery market between 2022 and 2030.
Medicinal drugs can be administered parenterally through two routes, intravenous and subcutaneous, using injectable drug delivery devices. Injectable method is most convenient for medications with low oral bioavailability and targeted drug delivery at the site of action. Compared to infusion method of drug administration that takes from 2 to 3 hours, injection method reduces time to only 5 to 7 minutes, thus significantly decreasing patient’s burden. It is used for treatment of hormonal imbalances, cystic fibrosis, Wilson’s disease, hemophilia, Hepatitis C, and ribose-5-phosphate isomerase deficiency, among other chronic diseases.
The global life science industry is experiencing a significant shift from chemical-based drugs toward biologics and biosimilars. Biologics are excellent for targeted delivery and have a lower risk of drug interaction, resulting in increased adoption. As biologics are being used more frequently to treat chronic diseases, drug and packaging manufacturers are seeking more sophisticated container closure and drug delivery systems. Demand for 2.25 mL needles has increased significantly following growth of the biologics and biosimilars market. As a result, use of injectable drug delivery devices for safely delivering biologics and biosimilars has increased significantly.
Request a Sample@ https://qyresearchmedical.com/sample/119030
The modern method of administering parenteral drugs use prefilled injections as a self-injecting device, which contribute to improved patient safety by reducing exposure to toxic products. Self-injecting devices with pre-measured dosage reduce dosing errors while increasing patient’s safety. Patients of type-1 diabetes are greatly dependent on injection of external insulin due to lack of hormones in body. Pre-filled syringes, pen needles, and auto-injectors are increasingly being adopted by diabetic patient pool for rapid and targeted insulin delivery within home premises, which is another factor driving injectable drug delivery market growth during the forecast period.
Driver: Increased use of contraceptive injectable is a key factor driving revenue growth of the market
Increasing demand for contraceptive injectable is a major factor driving demand for injectable drug delivery products. Contraceptive injections contain hormones that enable women to prevent pregnancy. Depot Medroxyprogesterone Acetate (DMPA) a progestin, which is the primary contraceptive hormone that provides reversible contraception for three months in an effective manner by suppressing ovulation and thickening cervical mucus. According to March 2022 estimates by the Guttmacher Institute and the World Health Organization (WHO), around 68% of total unintended pregnancies end up in abortions globally, with regions such as Latin America and sub-Saharan Africa, having unintended pregnancy rates ranging from 41 to 107 per 1,000 women and 49 to 145 per 1,000 women respectively. Use of contraceptives is expected to increase rapidly over the coming years following prohibition of abortion in several countries and amendment of laws to make it a punishable offense. DMPA shots can be administered either by clinicians or by patient themselves and it prevents fertilization of ovum through sperm. It also has a number of non-contraceptive advantages over estrogen-based contraceptive alternatives. For instance, DMPA does not cause severe side effects such as thromboembolism and can be used by patients who are unable to use estrogen-containing products. Furthermore, dysmenorrhea is reduced, in turn, reducing risk of endometrial and ovarian cancer.
Controlled delivery of drugs into tissues and organs and increased bioavailability of drugs administered through injection are some other factors expected to support market revenue growth over the forecast period. Intravenous injection method is rapid and enables 100% bioavailability of drug, which increases preference of healthcare providers and patients, to use injectable systems for delivery of drugs with poor bioavailability through oral administration. Poorly water-soluble drugs and Active Pharmaceutical Ingredients (APIs), which are becoming increasingly prevalent have lower rate of absorption in gastrointestinal tract when taken orally. Intravenous and subcutaneous drug injection methods are potential alternatives that enhance absorption and are expected to be increasingly adopted in the healthcare sector over the coming years. Subcutaneous injectable can be self-administered, which enables patients to take doses at home and reduce patient’s burden to visit medical centers. Orally administration requires higher concentration of drugs for optimal effect. Reducing drug concentration through injectable, which specifically deliver medications to target tissues and organs, will economically benefit manufacturers as well as consumers.
Restraint: Difficulties in design and development of novel auto-injectors is restraining market revenue growth
Injectable devices, such as auto-injectors, have to be designed and developed in accordance to drug formulations, patient needs, therapies, and stakeholders’ criteria. In addition, drug viscosity and drug volume, along with needle size and profile, injection volume, barrel, stopper, and needle shield components, influence format, specifications, and design of prefilled syringes. The ‘one-size-fits-all’ approach is not applicable for manufacturing auto-injectors, but increases cost and restrains revenue growth of the market to a considerable extent.
Injectables are invasive and painful, resulting in shift of patient’s preference toward oral, topical, and nasal drug delivery alternatives. Oral route is most preferred, because it is simple and convenient to use, cost-effective, and safe. Development of cost-effective insulin delivery alternatives, such as Veo insulin pump of Medtronic, is replacing injectable insulin devices. Rising prevalence of diabetes has resulted in increasing demand for external insulin, thus insulin injections account for a significant revenue share in the injectable drug delivery market. However, introduction of inhalable insulin is expected to have a significant impact on market growth because nasal drug delivery is pain-free and highly patient-compliant. In addition, development of alternative delivery techniques for other disease indications, such as oral anemia treatment by GlaxoSmithKline and Bayer, is expected to have a negative impact on injectable drug delivery market growth during the forecast period. Also, regulations of pharmaceutical prices in several countries restricts trade-mark-ups and limits profit margin. This, coupled with stringent quality control and standardization to avoid any medical adversity, is restraining revenue growth of the market to a considerable extent
The global injectable drug delivery market has recovered significantly after experiencing a setback during COVID-19 pandemic. Supply chain disruptions, implementation of lockdowns, price fluctuations, and temporary suspension of trade have contributed to contraction of global economy by 3.4% in 2020. Rising number of coronavirus disease cases led to postponement of all non-essential medical procedures and surgeries, which has negatively impacted the injectable drug delivery market during the first quarter. However, approval for use of antiviral drugs and monoclonal antibodies by regulatory bodies and development of vaccines by pharmaceutical companies have led to a rapid increase in product demand for administering medicinal formulations in COVID patients. Launch of new drugs is expected to increase adoption of different injectable systems by patients and healthcare providers for efficient delivery of medicine in patient’s body.
Device Type Insights:
Based on device type, the global injectable drug delivery market is segmented into conventional injectable, pre-filled syringes, auto-injectors, and pen-injectors. The pre-filled syringes segment is expected to account for a significantly large revenue share over the forecast period owing to increasing demand of innovative and convenient drug delivery options that enable unit dose medication. Patients are able to self-administer injectable medications at home rather visiting hospitals, which reduces patient burden for doctors, enabling pharmaceutical companies to reduce wastage of drugs and extend shelf-life of products. Diabetic patients account for a significant share of pre-filled injectable devices as they regularly need to externally inject insulin to maintain blood glucose levels. According to American Diabetes Association, around 7.4 million diabetic patients regularly use one or more insulin formulations in the U.S. Safety concerns and increasing preference toward cost-effective solutions have led to a drastic shift from glass syringes to plastic and disposable syringes as the most commonly used injectable devices. Also, pre-filled syringes are commonly employed in therapeutic disciplines such as vaccinations, blood stimulants, and therapeutic proteins. Pre-filled syringes make injections simpler and safer for doctors and patients enabling delivery of correct dosage on every use. Additionally, pre-filled syringes are compatible with an increasing number of popular safety devices and auto-injection systems.
The auto-injectors segment is expected to register a rapid CAGR over the forecast period. Several factors including safety, convenience, and ease of use, along with improved environmental sustainability and ability to configure technology of auto-injectors are expected to drive revenue growth of this segment. These injectable devices are automated and ensure rapid delivery of fixed amount of drugs in patients. Auto-injectors suitable for 1mL and 2.25mL prefilled syringes have been commercially available for past few years and have been gaining adoption due to increasing prevalence of chronic diseases, such as diabetes and cancer, which requires regular medicinal interventions. This is expected to drive revenue growth of this segment over the forecast period.
Product Type Insights:
Based on product type, the global injectable drug delivery market is segmented into freeze-dried products and injectable sterile products. The injectable sterile products segment revenue is expected to register faster growth rate during the forecast period owing to increased demand for biological drugs. In addition, increased demand for cardiac medicines, antibiotics, and analgesics, as well as regular intravenous glucose, potassium, and saline solutions has fueled market expansion. For example, intravenous infusion is a sterile injectable medicine that provides immediate therapeutic effect by swiftly delivering medication straight into bloodstream. Sterile injectable are generally formulated as concentrated admixtures that need to be diluted before use to eliminate microbiological contamination such as fungi and bacteria. Additionally, sterilization can also be performed by radiation exposure or gamma radiation, but other options including infrared and ultraviolet radiation, as well as high-velocity electrons are also available. Radiation is typically used to sterilize single-use components or systems, but it can also be used to sterilize packaged drug products.
The freeze-dried products segment is expected to register a steady growth rate over the forecast period. Freeze-drying, or lyophilization is the process of removing water from pharmaceutical and biological products, thereby dehydrating it to prolong shelf life of injectable. This enables patients and healthcare providers to store and transport medicines and drugs over long distances. Freeze-dried products have gained traction from patients who prefer self-administration devices, as this allows patients to purchase medications in bulk and use them as per their requirements, by diluting lyophilized product in specific solvents. This is expected to support revenue growth of this segment over the coming years.
Based on end-use, the global injectable drug delivery market is segmented into hospitals, homecare settings, clinics, and others. The hospitals segment is projected to account for a significantly large revenue share from 2022 to 2030. Healthcare providers in hospitals regularly employ injectable devices to administer vaccines, monoclonal antibodies, and other medications through intravenous or subcutaneous route of delivery. Operating rooms and intensive care units heavily rely on generic injectable for administration of drugs prior to surgery. Patients undergoing routine general anesthetic receive five or more different classes of injectable drugs. Clinicians working in these specific units require several other classes of injectable, such as antiarrhythmics and vasopressors, for management of potential complications arising from anesthesia and surgery.
Based on regional analysis, the injectable drug delivery market in North America accounted for largest revenue share in 2021. This is due to rapid rise in use of contraceptive medications, specifically contraceptive injectable following implementation of laws prohibiting abortion in several countries in the region. Contraceptive medications enable women to avoid unwanted pregnancies at an early stage. Robust presence of key players in the region and rapid innovation in injectable devices to cater to need of patients are some other factors boosting North America market revenue growth.
The Europe injectable drug delivery market is projected to register a rapid growth rate between 2022 and 2030, owing to rising prevalence of chronic diseases, expansion of the biologics and biosimilars market due to availability of novel formulations, increased medical technology advancements, rising geriatric population, and widespread use of self-injectable prefilled syringes in the region. Countries in Europe are experiencing a rise in demand of vaccines, insulins, as well as medicines required for treatment of several chronic diseases including cancer. Growth of the biologics market is expected to support growth of injectable drug delivery market as most biologics and biosimilars have to be administered intravenously. Moreover, acquisitions, partnerships, and significant investments by key players are expected to drive market revenue growth. In May 2022, EureKING, which is a biomanufacturing-focused special purpose acquisition company, has announced to raise USD 158 million to acquire various Contract Development and Manufacturing Companies (CDMOs) in the European region.
The Asia Pacific market is expected to register a steady growth over the forecast period. The region has rapidly adopted injectable drug delivery across healthcare sectors due to increase in geriatric population and chronic diseases such as diabetes and cancer. For instance, according to International Diabetes Federation, the South-east Asia region has 88 million diabetic patients, of which India accounts for 77 million of patient pool. Government initiatives, such as Ayushman Bharat to enhance diagnostic and treatment facilities, are expected to increase demand for injectable drug delivery devices in the country. Chemotherapy and other essential drug treatments use injectable devices to help patients feel better. Moreover, rapid adoption of innovative medical technologies, such as pre-filled syringes, has contributed to an increase in demand for injectable. Furthermore, factors such as rising healthcare expenditure and increased healthcare awareness and government funding, are contributing to market growth in this region
Competitive landscape of global injectable drug delivery market is fragmented with many key players operating on global and regional levels. These players are engaged in product development and strategic alliances to expand their respective product portfolio and gain a robust footing in the global market. Major companies in the market include Vetter Pharma, Akorn Operating Company LLC., Catalent, Inc., Pfizer Inc., Gerresheimer AG, Elcam Medical, Schott, SHL Medical AG, Becton, Dickinson & Company, and West Pharmaceutical Services, Inc.
- In January 2022, DALI Medical Devices, a producer as well as distributor of drug delivery devices in Yavne, Israel, launched SAN-Light passive safety needle along with novel drug products, enabling user-friendly administration. SAN-Light is a hypodermic safety needle for single-use which can be used with any Luer-lock syringe for drug administration.
- In November 2021, Becton, Dickinson and Company, based in Franklin Lake, New Jersey, U.S., launched BD Ultrasafe Plus 2.25 ml Passive Needle Guard for use in drug-device combo products by pharmaceutical companies. BD UltraSafe PlusTM 2.25 mL’s innovative design complements biopharmaceutical companies’ to combine effective product strategy by enabling patient-controlled injection for complex and high-viscosity medicines.
Segments Covered in the Report
This report offers historical data and forecasts revenue growth at a global, regional & country level and provides analysis of market trends in each of the sub-segments from 2022 to 2030. For this study, Reports and Data has segmented the injectable drug delivery market based on device type, product type, end-use, and region:
Injectable Drug Delivery Market Report Scope
Segments covered By Device Type Outlook, Product Type Outlook, End-Use Outlook, Regional Outlook
By Device Type Outlook
By Product Type Outlook
Injectable Sterile Products
By End-Use Outlook
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/119030/1500
You can place an order or ask any questions, please feel free to contact firstname.lastname@example.org | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: